🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. TAK-058 (ENV8058)

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    1 trial

  2. TAK-063

    Takeda

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  3. TAK-063

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  4. TAK-071

    Takeda

    Alzheimer Disease

    phase 1 small molecule terminated

    1 trial

  5. TAK-079

    Takeda

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  6. TAK-079

    Takeda

    Autoimmune Disease

    phase 1 small molecule completed

    1 trial

  7. TAK-079

    Takeda

    Systemic Lupus Erythematosus

    phase 1 small molecule completed

    1 trial

  8. TAK-102

    Takeda

    Solid Tumors

    phase 1 mab terminated

    1 trial

  9. TAK-103

    Takeda

    Solid Tumors

    phase 1 mab terminated

    1 trial

  10. TAK-105-a

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  11. TAK-114 10 mg capsule

    Takeda

    Clinical Pharmacology

    phase 1 small molecule completed

    1 trial

  12. TAK-117

    Takeda

    Metastatic Solid Tumors

    phase 1 small molecule completed

    1 trial

  13. TAK-117

    Takeda

    Neoplasm, Advanced or Metastatic

    phase 1 small molecule completed

    1 trial

  14. TAK-123

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  15. TAK-137

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    1 trial

  16. TAK-137

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 1 small molecule terminated

    1 trial

  17. TAK-137 5 mg tablet, TAK-137 placebo tablet

    Takeda

    Healthy Japanese Adult Male

    phase 1 small molecule terminated

    1 trial

  18. TAK-164

    Takeda

    Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

    phase 1 small molecule terminated

    1 trial

  19. TAK-165

    Takeda

    Breast Neoplasm

    phase 1 small molecule completed

    1 trial

  20. TAK-227

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  21. TAK-228

    Takeda

    Advanced Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  22. TAK-233

    Takeda

    Clinical Pharmacology

    phase 1 small molecule completed

    1 trial

  23. TAK-272

    Takeda

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  24. TAK-272

    Takeda

    Japanese Healthy Adult Males

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources